BDF Gestion Has $2.51 Million Stake in Laboratory Co. of America Holdings (NYSE:LH)

BDF Gestion lowered its stake in shares of Laboratory Co. of America Holdings (NYSE:LH) by 11.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 10,923 shares of the medical research company’s stock after selling 1,420 shares during the period. BDF Gestion’s holdings in Laboratory Co. of America were worth $2,505,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. SouthState Corp bought a new position in Laboratory Co. of America in the 3rd quarter worth $28,000. Horizon Bancorp Inc. IN acquired a new stake in shares of Laboratory Co. of America during the 3rd quarter valued at about $29,000. Fortitude Family Office LLC boosted its position in shares of Laboratory Co. of America by 312.5% during the 4th quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 100 shares in the last quarter. Geneos Wealth Management Inc. boosted its position in shares of Laboratory Co. of America by 309.8% during the 4th quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 127 shares in the last quarter. Finally, Riverview Trust Co boosted its position in Laboratory Co. of America by 172.6% in the third quarter. Riverview Trust Co now owns 169 shares of the medical research company’s stock valued at $38,000 after buying an additional 107 shares in the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Laboratory Co. of America Price Performance

Shares of LH opened at $246.36 on Thursday. The firm has a market capitalization of $20.61 billion, a PE ratio of 47.65, a PEG ratio of 1.81 and a beta of 1.06. The company’s 50-day moving average is $235.43 and its 200-day moving average is $227.96. Laboratory Co. of America Holdings has a fifty-two week low of $191.97 and a fifty-two week high of $250.56. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.44 and a quick ratio of 1.30.

Laboratory Co. of America Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 12th. Investors of record on Thursday, February 27th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend is Thursday, February 27th. Laboratory Co. of America’s dividend payout ratio is 55.71%.

Insider Buying and Selling

In other Laboratory Co. of America news, Director Kerrii B. Anderson sold 1,000 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $235,000.00. Following the sale, the director now directly owns 12,722 shares in the company, valued at $2,989,670. This represents a 7.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Adam H. Schechter sold 6,189 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $243.47, for a total transaction of $1,506,835.83. Following the completion of the sale, the chief executive officer now owns 87,441 shares in the company, valued at approximately $21,289,260.27. The trade was a 6.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,572 shares of company stock valued at $5,915,209. 0.85% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Bank of America boosted their price target on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Hsbc Global Res raised shares of Laboratory Co. of America from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 30th. Evercore ISI raised shares of Laboratory Co. of America from an “in-line” rating to an “outperform” rating and boosted their price target for the stock from $260.00 to $265.00 in a research note on Tuesday, January 7th. UBS Group lowered their target price on shares of Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $275.00 target price (up previously from $265.00) on shares of Laboratory Co. of America in a research note on Tuesday, December 10th. Four analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $261.77.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.